Join us: The Markers in Neuropsychiatric Disorders (MiND) Study is exploring the benefits of a new blood test for early and accurate identification of dementia and neuropsychiatric disorders.
“High levels of Neurofilament light (NfL), a biomarker of nerve cell injury, have been found to distinguish dementia from psychiatric illness and non-dementia, with high-accuracy,” says Professor Dennis Velakoulis, Director of Neuropsychiatry and Study Lead at the Royal Melbourne Hospital (RMH).
According to Chief Investigator of the Study and PhD student, Dr Dhamidhu Eratne, “The MiND Study will demonstrate how well a blood test for NfL works, in a large number of people with diverse symptoms, and in broad settings such as primary care, all over Australia. Our ultimate aim is clinical translation: to lead to a simple, routinely available blood test for GPs and other specialists, to help reduce misdiagnosis and delay to accurate diagnosis and treatment, and improve outcomes for patients, their families, and healthcare systems”.
The study is welcoming referrals from general practitioners nationally for patients aged 40–80, with recent (within five years) cognitive, psychiatric, and/or neurological symptoms. Eligibility criteria is available online. All that’s needed is a 2-minute online referral form. The study team will take it from there, managing all aspects of patient recruitment. The main requirement for patients is also minimal: a simple blood test, which can be done close to home.
To learn more about this game-changing research in #Neuropsychiatry @RMH, please visit – www.themindstudy.org
Get social with the Study team @themindstudy
Welcome to the Gold Coast Primary Health Network
So we can provide you with the most accurate information,
please tell us a little more about yourself